title: Persistence of anti-HLA antibody after cord blood transplantation engraftment in acute myelogenous leukemia: a potential marker of minimal residual disease, but not a significant factor in secondary humoral engraftment failure.
abstract: The presence of pre-transplant anti-HLA antibodies in recipients of cord blood transplantation (CBT) is associated with failed engraftment. However, only a small number of studies have reported that recipient-derived anti-HLA antibodies persist after CBT and have potential impact on the outcome. Of 61 patients who underwent HLA-mismatched CBT at Saiseikai Maebashi Hospital, three patients were identified as having anti-HLA antibodies not corresponding to HLA antigens in the transplanted CB. All patients achieved successful engraftment. However, the three patients with the pre-transplant anti-HLA antibodies not corresponding to HLA antigens in the transplanted CB continued to produce these antibodies even after engraftment; the persistence of these antibodies served as a sensitive minimal residual disease (MRD) marker. In contrast, donor HLA-specific and newly produced third party antibodies were not detectable even after relapse. The persistence of anti-HLA antibodies even after engraftment may be a potential marker for MRD, but is not a significant factor in secondary humoral engraftment failure.
authors: Leukemia Research Center, Saiseikai Maebashi Hospital, Kamishinden-machi, 564-1 Maebashi, Gunma, Japan. takumihoshino4249@gmail.com
authors: Takumi
authors: T
authors: Hoshino
authors: Satoru
authors: S
authors: Takada
authors: Kenichi
authors: K
authors: Tahara
authors: Hiroaki
authors: H
authors: Shimizu
authors: Nahoko
authors: N
authors: Hatsumi
authors: Shuichi
authors: S
authors: Miyawaki
authors: Tohru
authors: T
authors: Sakura
mesh_terms: D000328:Adult; D000906:Antibodies / Q000097:blood / Q000276:immunology*; D015415:Biomarkers / Q000097:blood; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000209:etiology; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000175:diagnosis / Q000276:immunology; D016879:Salvage Therapy; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; D015415:Biomarkers; D006680:HLA Antigens